Cartilage oligomeric matrix protein (COMP) is a member of the thrombospondin family of extracellular matrix glycoproteins. All members of the family contain a highly conserved region of thrombospondin type 3 sequence repeats that bind calcium. A mutation in COMP previously identified in a patient with pseudoachondroplasia resulted in abnormal sequestration of COMP in distinctive rER vesicles. The mutation, Asp-446 3 Asn, is located in the type 3 repeats of the molecule. This region was expressed in a mammalian culture with and without the mutation to study the structural or functional properties associated with the mutation. The biophysical parameters of the mutant peptide were compared with those of the wild type and revealed the following difference: secondary structural analysis by circular dichroism showed more ␣-helix content in the wild-type peptides. The calcium binding properties of the two peptides were significantly different; there were 17 calcium ions bound/wild-type COMP3 peptide compared with 8/mutant peptide. In addition, wild-type COMP3 had a higher affinity for calcium and bound calcium more cooperatively. Calcium bound by the wild-type peptide was reflected in a structural change as indicted by velocity sedimentation. Thus, the effect of the COMP mutation appears to profoundly alter the calcium binding properties and may account for the difference observed in the structure of the type 3 domain. Furthermore, the highly cooperative binding of calcium to COMP3 suggests that these type 3 sequence repeats form a single protein domain, the thrombospondin type 3 domain.
Cartilage oligomeric matrix protein (COMP)
1 is a member of the thrombospondin (TSP) family of extracellular glycoproteins (1) . Like the other four members of the gene family, COMP is an oligomer composed of identical subunits (2) . The chains associate at the N terminus through a coiled-coil domain. Assembly of the oligomer requires the formation of an ␣-helical coiled-coil domain that is later stabilized by interchain disulfide bonds (3) . Electron microscopy shows the COMP molecule to be composed of five flexible arms with a large globular domain at the end of each arm and often described as being bouquet-like in its appearance (4) . TSP 3 and 4 also form pentamers (4 -6), whereas TSP 1 and 2 are trimeric molecules (2) .
The TSP family members have in common the domain structure typified by the oligomerization domain, three or four epidermal growth factor domains (EGF), and an invariant number of thrombospondin type 3 sequence repeats considered as seven or eight domains, the number depending on how the amino acid sequence is aligned (2) . A comparison of TSP 1, 2, 3, and 4 with COMP sequence reveals a high degree of conservation in the type 3 repeats. The temporal and spatial expression pattern of the TSP family members is distinctive, although somewhat complementary and occasionally overlapping (7) . COMP was originally discovered in cartilage extracts and has been immunolocalized to developing as well as mature cartilage (8, 9) . COMP has also been found within and around the tendon (10) .
There are no known human pathologies associated with the thrombospondin family members with the exception of COMP. In the last few years COMP mutations have been identified in two dominantly inherited skeletal disorders: pseudoachondroplasia (PSACH) and multiple epiphyseal dysplasia (MED). These osteochondrodysplasias result from base substitutions, deletions, or additions in the COMP gene. PSACH is characterized by a disproportionate short stature and joint laxity. Manifestations of PSACH usually first appear at the onset of walking with a distinctive waddling gait. MED patients generally present with debilitating hip pain in childhood. Short stature maybe observed later in childhood. The radiological abnormalities of MED are restricted to the epiphyses, whereas there is additional involvement of the metaphyses and the spinal column in patients with PSACH. Patients with both disorders manifest symptoms of precocious osteoarthritis.
Another extracellular matrix component of cartilage, type IX collagen, has also been implicated in MED. This form of MED (EDM2) was mapped to chromosome 1p32, and the locus was identified as the COL9A2. Mutations have been identified in COL9A2 (11) . A third MED locus has recently been mapped to COL93A, and a mutation was identified (12) . There seems to be a growing consensus that the phenotypes of the MED patients with known type IX collagen mutations are less severe than those with COMP mutations (12) . However, there is a variation in the severity of symptoms within families of a known single mutation creating a complex genetic or physiological explanation. Unlike MED that can result from mutations in one of three genes, PSACH is only associated with mutations in the COMP gene.
The mutations in COMP associated with PSACH and MED predominantly occur within the thrombospondin type 3 re-peats, the region proposed to bind calcium (13, 14) . The presumed importance of calcium binding to the biological function of COMP is largely based on studies of TSP 1 demonstrating that calcium binding occurs in a cooperative manner and protects against proteolysis (15, 16) . No structural information is known about these type 3 repeats. This region contains 17 cysteines and a large number of acidic residues; it also contains 13 putative EF hands. The structural conformation of these repeats therefore is expected to be highly sensitive to the presence of calcium (17) . To determine the effect of the Asp-446 3 Asn mutation on these sequence repeats, we have expressed wild-type and mutant peptides in a mammalian cell culture system.
Earlier biochemical methods to isolate COMP from cartilage have demonstrated the importance of cationic interactions. COMP was selectively extracted using the cationic chelator EDTA (4). This suggests that COMP is secured in the cartilage matrix through cationic interactions and further demonstrates the potential importance of calcium binding and the effect of a mutation at one of these sites. A second cation, zinc, has been proposed to promote COMP interactions with collagen types I and II (18) . This interaction occurs between the collagen triple helical domains and the globular C terminus of COMP. The interactions of these two cartilage matrix components, COMP and type II collagen, suggest a crucial biological function of COMP. In comparison, there is very little information on ligands that form molecular interactions with the type 3 repeats of COMP.
The fate of a COMP molecule in PSACH has been established for the Asp-446 3 Asn mutation: COMP is sequestered inside the rER vesicles (19) . It was also determined in this study that type IX collagen was found in these vesicles as well. The stored material is organized into a lamellar pattern of alternating electron dense and lighter layers with COMP and type IX localizing to the more dense layers (19) . Earlier studies of aggrecan have also shown it to be present in the enlarged rER vesicles (20, 21) . In contrast to these cartilage macromolecules, type II collagen is secreted and assembled into the extracellular matrix of PSACH cartilage (19) . The secretory pathways for aggrecan and type II collagen differ (22) , and presumably the pathway for aggrecan is shared by COMP and type IX collagen.
These investigations present a complex scenario where mutations in COMP cause a gross accumulation of cartilage-specific macromolecules. Assuming that the wild-type allele is transcribed and translated at approximately the same rate as the one containing the mutation, then probability suggests that 97% of the molecules will contain one or more mutant polypeptide chains. However, it is not known if the mutant chains fold properly and are subsequently assembled into COMP pentamers. Also unknown is whether the mutant molecules interact with other cartilage components retained in the rER (i.e. aggrecan and type IX collagen) in a specific manner or if the secretion of the aberrant molecule is retarded, potentially causing nonspecific aggregation. In this report, we describe the specific structural consequences of the mutation in the thrombospondin type 3 domain.
EXPERIMENTAL PROCEDURES
Transgene Expression of COMP Peptides in 293 Cells-Primary chondrocytes were isolated as described previously from PSACH patient cartilage (19) and cultured for up to eight passages. The region containing the TSP type 3 repeats was amplified following reverse transcription of total RNA (Life Technologies, Inc., Superscript Preamplification Kit) using a forward primer that contained an NheI cleavage site (5Ј-agtagctagctggtcgcgacactgacctagac-3Ј), whereas the reverse primer contained an NotI site (3Ј-ccpgagaacgctgaagtcacgtaggcggccgcatttgata-5Ј).
The resulting polymerase chain reaction bands were gel-purified and ligated into the pCRII vector (Invitrogen). One wild-type clone and one carrying the PSACH mutation were selected following cDNA sequence analysis of the plasmids. These COMP3 cDNA fragments were excised from the pCRII sequencing vector with NheI and NotI and ligated into the respective cloning site in the expression vector pCEPSP-rF17H (23). This vector was derived from plasmid pCEP4 (Invitrogen) and engineered to contain the signal sequence of BM40 for secretion of the peptide into the extracellular medium (24, 25) . The pCEP-COMP3 expression vectors were cultured in DH52 cells and DNA-isolated under sterile conditions. For stable episomal expression, human embryonic kidney cells (293-EBNA cells, Invitrogen) were transfected with the pCEP-COMP3 constructs in the presence of calcium chloride (25) . Selection antibiotics Geneticin (Life Technologies, Inc., G418) and hygromycin-B (Calbiochem) were added to the cell culture medium 48 h after transfection at a concentration of 500 g/ml. The concentration of antibiotics was reduced to 250 g/ml following an additional 48 h. Serum-free medium was collected and tested for the presence of the COMP3 peptides using SDS-polyacrylamide gel electrophoresis. The gel band was identified as COMP3 by N-terminal sequencing following transfer to a polyvinylidene difluoride membrane (the first ten residues were APLAGRDTDLD). The COMP3 peptide starts with APLA, the C terminus of the signal sequence; the remainder of which is removed following processing and secretion.
Purification of the COMP Peptides-Medium from the cultured cells was collected and fractionated with ammonium sulfate. The COMP3 peptides remained in the 60% ammonium sulfate supernatant following precipitation and centrifugation. After dialysis into 20 mM Tris/HCl buffer, pH 8.0, the supernatant was applied to a Q-Sepharose ionexchange column (Amersham Pharmacia Biotech) and eluted with a NaCl gradient from 0 to 1 M in the same buffer. Pooled fractions containing the COMP3 peptides were further separated by molecular sieve chromatography on a Superose-12 column (Amersham Pharmacia Biotech) in 50 mM Tris/HCl buffer, pH 7.4, containing 0.15 M NaCl.
Structural Analysis of the COMP3 Peptides-Circular dichroism (CD) spectra of the COMP3 peptide in 10 mM MOPSO, pH 6.8, was analyzed in the presence and absence of 5 mM calcium chloride at 5°C. The spectra was recorded between 260 and 180 nm on a Jasco J-500A or Aviv 202 spectropolarimeter using thermostatted cells for temperature. Secondary structural analysis was determined using a variable selection method (26, 27) . Tertiary structure was analyzed by velocity sedimentation in a sucrose gradient (50 mM Tris, pH 7.5, containing 150 mM NaCl and 5-20% sucrose). Peptide solutions at concentrations of 10 M were prepared in the presence of either 5 mM CaCl 2 or 5 mM EDTA tetrasodium. The centrifugation was performed for 20 h at 56,000 rpm at 4°C in a Beckman L80M ultracentrifuge using an SW 60Ti rotor. Sedimentation coefficients were calculated as described previously (28) . The molecular weight of the COMP3 peptide was assessed by equilibrium sedimentation using a Spinco Model E centrifuge (Beckman) at 17,000 rpm at 20°C in double sector cells (29, 30) .
RESULTS
The COMP molecule is composed of five identical polypeptide chains and within each chain is a linear arrangement of domains or repeated domains (Fig. 1A) . The Asp-446 3 Asn mutation previously characterized in a PSACH patient (19) occurred in the type 3 repeats where the majority of COMP mutations associated with skeletal pathologies also occur (13, (31) (32) (33) . Thus, this region was selected to be expressed in a recombinant cell culture system and analyzed.
Expression of Recombinant COMP3 Peptides-The COMP3-Wt and -Mu constructs were derived from RNA isolated from a PSACH patient with a g 3 a base substitution at position 1361 of the coding sequence that resulted in the substitution of asparagine for aspartic acid (19) . Utilizing an expression system previously described for other secreted extracellular matrix molecules (24, 25) , COMP3 peptides were expressed in human embryonic kidney cells (293-EBNA cells). The first step of protein purification was ammonium sulfate fractionation of the cell culture medium followed by column chromatography. The COMP3 peptides remained in solution at 60% saturation (Fig. 1B) . Following dialysis of the ammonium sulfate supernatant, the peptides were further purified by cation exchange and size exclusion chromatography (Fig. 2, A  and B) .
Rotary Shadowed Images of COMP3 Peptides-Rotary shadowed images of COMP molecules indicate that the arms are flexible rods that connect the "stalk" of the bouquet (the coiledcoil domain) to the globular domain (4) . These arms are composed of 4 EGF-like and type 3 repeats. It is presumed that EGF-like repeats form small globular domains that are aligned linearly from the solution structural determination of a pair of EGF-like domains (34). It is not known what the type 3 repeat structures are or how they are organized relative to one another. From the data presented here (Fig. 3A) , COMP3-Wt peptides appear to be short rods with an average length of 14.2 nm Ϯ 1.68 (n ϭ 28). This measurement is consistent with that based on the rotary shadowed images of native COMP molecules. The reported distance between the coiled-coil and the middle of the globular domain of a full-length COMP subunit is 28.6 nm (4). The 4 EGF-like domains would be ϳ12 nm based on the structural measurements of one EGF-like domain in human factor IX (35) . This would leave 16.4 nm for the TSP type 3 repeats and half of the terminal globule based on these reported molecular measurements. Thus, the length of the COMP3-Wt peptide at 14.2 nm is structurally consistent with the native wild-type COMP domains.
The COMP3-Mu peptides were shorter with an average length of 10.3 nm Ϯ 1.68 (n ϭ 35; Fig. 3B ). Whereas the size of these peptides is small and near the limit of resolution of the rotary shadow technique, the measured differences between COMP3-Wt and -Mu are supported by additional measurable variations between the two species of peptides. It is likely that the mutation affected the overall structure of COMP3-Mu.
Structural Analyses of the COMP3 Peptides-Differences in secondary structure were observed in circular dichroism spectra between peptide populations in the presence and absence of calcium (Fig. 4A) . Analysis of the spectra indicates that the differences were notable in the loss of helical structure and an increase in the antiparallel ␤-sheets in COMP3-Mu compared with COMP3-Wt peptides (see Table I ). The change in the secondary structure was directly coupled to the presence of calcium. Titration experiments with calcium showed a cooperative structural change for both peptides (Fig. 4B ). However these experiments did not allow the determination of the number of binding sites; therefore we measured calcium binding by equilibrium dialysis (see below).
Molecular Weight Determination of COMP3 Peptides-The molecular weights of COMP3-Wt and -Mu peptides were measured by sedimentation equilibrium in a model E analytical ultracentrifuge. The solutions showed monodisperse species with molecular masses of 31,260 Ϯ 170 Da for COMP3-Wt and 30,780 Ϯ 100 Da COMP3-Mu (data not shown). The partial specific volume was calculated from the amino acid composition and found to be 0.678 cm 3 /g (36) , and the degree of hydration was estimated to be 0.3 g/g. A comparison of the measured molecular weights with the molecular mass determined from the amino acid sequence (28, 632 Da) indicates that the COMP3 peptides have little or no post-translational modifications (such as glycosylation). The slightly higher molecular weight of the COMP3-Wt peptides could be a reflection of more bound calcium (see below).
Sedimentation Velocity Experiments in Sucrose GradientsThe COMP3 peptides were analyzed for shape by centrifugation in 5-20% sucrose gradients in the presence and absence of calcium (Fig. 5 ). Sedimentation coefficients s 20,w in the absence of calcium were 2.5 Ϯ 0.1 S and 2.7 Ϯ 0.1 S for the wild-type and mutant peptide, respectively. In the presence of calcium the sedimentation coefficient of the wild-type peptide changed to 2.8 Ϯ 0.1 S, whereas the mutant peptide showed no change in s 20,w value. The increase in s 20,w of 2.5 to 2.8 for COMP3-Wt peptides indicates a significant change in the frictional ratio upon binding of calcium. This would be consistent with an earlier study of thrombospondin 1 that demonstrated an elongation of the subunit "arms" in the presence of EDTA (37) . Using the determined sedimentation coefficient and molecular weight of COMP3-Wt and assuming the degree of hydration is 0.3 ml/g, the frictional ratio is 1.38 in the presence of calcium. This frictional ratio indicates that the hydrodynamic dimensions of the wild-type COMP3 peptide are 15.0 ϫ 2.1 nm for a prolate ellipsoid or 13.4 ϫ 1.8 nm for a rod. The measured length of the rotary shadowed image of the wild-type peptide, 14.2 nm, is consistent with these calculations.
Calcium Binding by Equilibrium Dialysis-One important but speculative function of the type 3 domains in the thrombospondin family is to bind calcium. COMP3 peptide solutions were dialyzed against concentrations of calcium chloride ranging from 50 M to 2 mM. A small amount of radiolabeled calcium was added for quantitative purposes. The free and proteinbound calcium concentrations were calculated for several experiments using protein concentrations that varied from 1.6 to 10.3 M (Fig. 6) . The resulting plot indicated that the number of bound calcium molecules/molecule was much lower for the COMP3-Mu peptides (8 compared with 17 for COMP3-Wt). The Hill coefficient, a measure of the cooperativity of the binding curve, showed COMP3-Wt bound calcium in a more cooperative manner (3.74 versus 1.57 for mutant COMP3) . Also, the concentration at half saturation was 102 and 218 M for wild-type and mutant peptide, respectively.
DISCUSSION
Data presented here show the first measurable consequence that relates a mutation in COMP to a molecular mechanism involved in generating the PSACH phenotype. This consequence is an altered potential for mutant COMP peptides to bind calcium. The secondary and tertiary structures are quantitatively affected by the reduced calcium binding. Most mutations in COMP are clustered within the type 3 repeats in the skeletal dysplasias PSACH and MED; presumably other COMP mutations alter molecular structure in a similar way.
The calcium binding data indicate a very complex scenario with a large number of potential binding sites and a highly cooperative mechanism for binding. The primary structure of the type 3 repeats conforms to the consensus sequence of the EF-hand motif, a common structure associated with calciumbinding proteins. Sites contain a stretch of amino acids represented by X, Y, Z, -X, -Y, -Z that provide coordinating oxygens for calcium-ligand interactions in a distinctive geometry. There are up to 13 such sites in the type 3 repeats that share homology with the EF-hand structure (16) compared with 17 calcium ions shown to bind the COMP3 peptides here. The difference suggests that the COMP3 peptide forms a more complex structure than that represented by linear repeated sequences.
The 17 potential binding sites determined for the COMP3 peptides are also higher than that previously calculated for TSP I where 35 Ϯ 3 ions of calcium bound one trimeric TSP I molecule (15) , which is approximately 12 calcium ions per polypeptide. One of these 12 is assumed to be bound to the EGF-like repeat with the consensus sequence of a calcium binding EGF domain; the COMP domain structure predicts two calcium binding EGF repeats based on residues crucial for ligand binding (38) . These differences may be because of slight variations in design of binding assays such as ligand concentration (15) or the small sequence differences between COMP and TSP 1.
In addition to the 13 EF-hand-repeating motif structure, the type 3 repeats have also been organized into 8 repeating units called 3A and 3B with the asparatic acid and cysteine residues aligned (39) . This alignment suggests that the cysteine residues may form intradomain disulfide bonds, thus stabilizing the eight repeated units. However, the disulfide bonds have not been established and it is difficult to see how more than eight calcium ions would bind with this domain structure. The structural organization of the type 3 repeats is commonly viewed as a series of separately folded motifs along the polypeptide chain, although no structural data have been presented to support or dispute this presumption. The highly cooperative calcium binding data presented here strongly suggest that these sequence repeats form a single protein domain. This is also supported by the sequence conservation within all five thrombospondin family members. If the peptide was composed of independently folded domains, one could expect more variations within these repeated sequences. Therefore we propose that the type 3 sequence repeats form a single protein domain: the TSP type 3 domain.
It is interesting to note that the mutant peptide bound less than half the normal amount of calcium and yet theoretically only one potential binding site would be directly affected. This suggests that other factors are involved. Calcium binding to TSP I occurs by a cooperative mechanism suggesting that there is a conformational change upon an initial binding event that effects the conformation of other sites. Thus, the impact of an amino acid mutation at one calcium binding site could greatly alter binding at other sites.
The reduced calcium binding in the mutant COMP peptide has significant biological relevance in view of the effect of COMP mutations on skeletal development. Following translation of a COMP polypeptide, the chains normally assemble into a mature pentameric COMP molecule and are trafficked through the Golgi and secreted. The sequestration of COMP by PSACH chondrocytes may potentially be the result of quality control mechanisms within the rER that retain incorrectly folded proteins. Unsecreted COMP would thus accumulate in the rER and possibly form aggregates that include COMP and other cartilage components such as aggrecan and type IX collagen. Both of these molecules have been shown to be retained intracellularly in PSACH chondrocytes (19, 20) . In another calcium binding molecule, fibrillin, calcium binding maintains the tertiary structure of two adjacent EGF-like domains (34) . The results suggested that the calcium bound at the interface between the domains fixes the domains in a linear orientation. It is important to note that there is a significant difference in the potential effect of loss of calcium binding in fibrillin compared with COMP. In contrast to the calcium bound to fibrillin, calcium binding to COMP occurs in a cooperative manner. Perhaps calcium stabilizes a particular structure in COMP that promotes proper folding, secretion, and matrix assembly.
The thrombospondin family members contain three regions that have been shown to or have potential to bind divalent cations: the two calcium binding EGF-like repeats, the type 3 domain with some homology to other calcium binding molecules, and the C terminus that has been shown to bind zinc (18) . Of these, the only ionic association with biological relevance is that of zinc binding, which permits interaction with collagens I and II at the C terminus. This interaction is enormously significant in that COMP is a component of tendon and cartilage, two tissues that are affected in PSACH by COMP mutations. From the data presented here that show altered conformation of COMP3 peptides with the Asp-446 3 Asn mutation, we speculate that the native molecular structure is also affected. It is likely that the interaction with fibrillar collagens and potentially other extracellular matrix components may be disrupted.
In conclusion, data presented here demonstrate a direct, specific, measurable effect of PSACH-associated COMP mutations on molecular properties. The mutation, Asp-446 3 Asn, reduces the potential of the COMP3 peptide to bind calcium ions resulting in a highly altered conformation. The secondary and tertiary structure was disturbed. With these results, it is proposed that the pathogenesis of PSACH includes the profound alteration of the type 3 domain and possibly the overall molecular structure. Future studies will be required to understand how the altered structure causes storage of selected cartilage components.
